Skip to content
Biotechnology

BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development

The BioMed X Institute 3 mins read

Powered by Sanofi, a new BioMed X research team will develop a computational platform designed to accelerate drug development.

HEIDELBERG, GERMANY / ACCESSWIRE / June 29, 2023 / BioMed X, a German independent research institute, announces the start of its first research project in collaboration with Sanofi: "Next Generation Virtual Patient Engine for Clinical Translation of Drug Candidates" (VPE). The end goal of this research project is to develop a versatile computational platform that can predict the efficacy of first- or best-in-class drug candidates in virtual patient populations at unprecedented accuracy, thereby addressing one of the most critical bottlenecks of the pharmaceutical industry today: a 90% failure rate of new drug candidates during clinical development.

The BioMed X Institute, Thursday, June 29, 2023, Press release picture



The new research team will be led by Dr. Douglas McCloskey, a scientist and entrepreneur jointly selected by the Sanofi and BioMed X Institute management for the group leader position. "Most drug candidates that fail during clinical development do so due to a lack of efficacy compared to the standard of care. Our mission is to develop a platform to test-drive drug development candidates in virtual patients to gate the best ones into the clinic," explained the newly-appointed group leader of team VPE. "To tackle this challenge, our team at BioMed X will push the frontier of in silico drug discovery and development using our AI expertise with coaching from our industry partners," added Dr. McCloskey.

Christian Tidona, Founder and Managing Director of the BioMed X Institute: "After two years of collaborating on AI-powered drug discovery and development projects with our strategic partner in Israel, AION Labs, we are now ready to start our first AI-based research team in Heidelberg, Germany, together with our new pharma partner, Sanofi."

The "Next Generation Virtual Patient Engine for Clinical Translation of Drug Candidates" (VPE) team joins eight other active research teams at the BioMed X Institute in Germany, and it is one of four new projects launched by BioMed X in 2023. To learn more about this new AI-based research group, visit the BioMed X Institute website at www.bio.mx.

About BioMed X

BioMed X is an independent research institute located on the campus of the University of Heidelberg in Germany, with a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world's brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds - academia and industry - and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.

Contact Information

Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706

SOURCE: BioMed X Institute

.


View source version on accesswire.com:
https://www.accesswire.com/763921/BioMed-X-Institute-Starts-Its-First-Research-Project-With-Sanofi-on-Artificial-Intelligence-for-Drug-Development

More from this category

  • Biotechnology
  • 10/02/2025
  • 11:48
BTC Health Limited (ASX:BTC)

BTC expands distribution partnership with Arna Pharma

• License and distribution agreement forBronchitol and Aridol converted from an initial 10- year term to an indefinite license • BTC to earn royalties from sales ofBronchitol and Aridol in Singapore and Malaysia • BTC granted first right of refusal to Arna Pharma's new product pipeline Melbourne, Australia: BTC Health (ASX: BTC) (BTC or the Company) is pleased to announce that its whollyowned investee company, BTC Pharma, has amended its existing License and Distribution Agreement for the Bronchitol and Aridol products (Products) and extended its partnership with Arna Pharma, with effect from 1 February 2025. Under the terms of the…

  • Biotechnology, Business Company News
  • 10/02/2025
  • 09:49
Jane Morgan Management

Leading Chicago Pediatric Cente, North Shore Pediatric Therapy, Joins BlinkLab’s US Autism Diagnostic Registrational Study

10 February 2025 – Sydney, Australia | BlinkLab Limited (ASX:BB1) ("BlinkLab" or "the Company"), an innovative digital healthcare company utilising AI-powered smartphone technology as part of a neurodevelopmental diagnostic approach, is pleased to announce that North Shore Pediatric Therapy (NSPT) has joined its US registrational study as the second clinical site. NSPT, a well-known provider of early autism intervention in the Chicago area of the United States, will play an important role in the 100-patient initial phase of the BlinkLab Dx 1 study, with patient recruitment and diagnostic testing set to begin in weeks to come. Highlights NSPT has joined…

  • Contains:
  • Biotechnology
  • 07/02/2025
  • 12:57
OncoSil Medical Limited (ASX:OSL)

OncoSil Medical (ASX:OSL) Investor Webinar Invitation

Sydney, Australia – 7 February 2025: Pancreatic cancer treatment device company OncoSil Medical Limited (ASX:OSL) will host an investor webinar on Tuesday 11 February 2025. The webinar will be presented by OncoSil’s Chief Executive Officer & Managing Director, Nigel Lange, and will be followed by a short Q&A session. In his webinar presentation, Mr Lange will discuss recent developments in the OncoSil™ device’s commercialisation strategy, including: An update on the German Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA) approval for the Directive for testing the new treatment method: "Endoscopic injection-implantation of 32Plabeled microparticles in unresectable, locally advanced pancreatic tumors." The authorisation…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.